Search Videos and More

Showing 1 - 12 of 62 results

Previous| 1 | 2 | 3 ...6 |Next


Molecular Tripwires and Sponges Evolved in Bacterial Struggle for Survival News

Molecular Tripwires and Sponges Evolved in Bacterial Struggle for Survival

Dana-Farber researchers have discovered ancient bacterial defenses and anti-defenses that may persist in some form in humans today and could provide insights into new approaches to cancer research and treatment. 
Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer News

Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.
Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025 News

Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.
Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study News

Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study

Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer
Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment News

Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment

Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care.
Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells News

Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells

Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation.
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research News

FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research

FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors
AI Learns Genomic “Language” to Advance Cancer Treatment News

AI Learns Genomic “Language” to Advance Cancer Treatment

The human genome is a sequence of Ts, Gs, Cs, and As that is about 3 billion letters long.  And, says Bradley Bernstein, MD, PhD, chair of Dana-Farber’s Department of Cancer Biology, “there’s no dictionary or guide for reading it.”  
Novel Stem Cell Therapy Safely Repairs Irreversible Corneal Damage in Clinical Trial News

Novel Stem Cell Therapy Safely Repairs Irreversible Corneal Damage in Clinical Trial

An expanded phase clinical trial that tested a groundbreaking, experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients who were treated and followed for 18 months, and there was a high proportion of complete or partial success.
Early Cancer Detection Studies for High-Risk People News

Early Cancer Detection Studies for High-Risk People

A blood test can now detect the presence of 50 different cancers — most of which do not have any other means of screening.
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings News

Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings

Dana-Farber Cancer Institute researchers presented key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.
A Year of Advances in Genitourinary Cancer News

A Year of Advances in Genitourinary Cancer

Dana-Farber’s genitourinary cancer team is devoted to research that will advance patient care and improve patient’s lives. Recently, that research — all of it years in the making — has paid off with major achievements.

Showing 1 - 12 of 62 results

Previous| 1 | 2 | 3 ...6 |Next